Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
Expands manufacturing push & locks in major growth deals
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Subscribe To Our Newsletter & Stay Updated
